Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Can Editas, BeiGene Offerings Redeem US IPO Class Of 2015?

This article was originally published in Scrip

Executive Summary

US initial public offerings by biotechnology companies in 2015 dried up in November, but since Editas Medicine Inc. and BeiGene Ltd. had strong offerings to kick off February, does that mean that dozens of drug developers will be able to go public again in 2016?


Related Content

Top Financings: 2018 Was A Remarkable Year For Biopharma Fundraising
Finance Watch: Not Everyone Can Go Public, But Biopharma IPOs Are Using Multiple Markets
Finance Watch: A Bountiful November Harvest For Venture-Backed Biopharma
IPO Update: Three Biopharma Offerings In January Contrast With Last Year’s Slow Start
VC Roundup: Flagship’s New Fund Designed To Raise Its Stake In Startups
IPO Update: Values Slip As Four More Biopharma Firms Go Public In October
VC Roundup: October Brings Several New Venture Funds, Including Third Rock’s Fourth



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts